Acumen Pharmaceuticals, Inc.

ABOS

Acumen Pharmaceuticals, Inc.

ABOS

Insider Sentiment (TTM):

Last Purchase:2023-07-21Last Sale:2026-06-17Shares Purchased (TTM):0Shares Sold (TTM):140,755

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:45,081,869Shares Outstanding:63,219,289Institutional Ownership Pct.:71.31%

Earnings Market Reaction:

Filing Date:2026-05-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Companies in Biological Products, (No Diagnostic Substances)

AMGN GILD SCLX BIIB MRNA RVMD

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	52	54	47	37	30	36	33	68	47	67	95	77
Marketable Securities Current	77	63	80	107	119	136	167	193	206	177	121	68
Prepaid Expense And Other Assets Current	5	5	6	5	6	7	7	6	3	3	3	5
Assets Current	133	122	132	148	155	178	208	267	256	247	219	150
Marketable Securities Noncurrent	-	0	9	23	49	60	59	21	44	63	67	27
Operating Lease Right Of Use Asset	-	-	-	-	-	-	0	0	0	0	0	0
Restricted Cash Noncurrent	0	0	0	0	0	0	0	0	0	-	0	-
Property Plant And Equipment Net	-	-	-	-	-	-	0	0	0	-	0	0
Restricted Cash	-	0	-	-	-	0	-	-	-	0	-	-
Other Assets Noncurrent	0	0	0	0	1	0	0	0	0	1	0	0
Property Plant And Equipment And Finance Lease Rig…	-	-	-	-	-	-	-	-	-	0	-	-
Assets	134	123	142	172	204	239	267	289	301	310	286	177
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	2	1	1	2	1	6	2	4	3	1	1	2
Accrued Liabilities Current	5	10	8	12	7	7	5	4	3	6	3	2
Finance Lease Liability Current	-	-	-	-	-	0	0	0	0	1	-	-
Operating Lease Liability Current	-	-	-	-	-	-	0	0	0	0	0	0
Short Term Borrowings	14	9	4	-	-	0	-	-	-	-	-	-
Liabilities Current	29	30	22	25	19	28	20	15	8	13	6	9
Operating Lease Liability Noncurrent	-	-	-	-	-	-	0	0	0	0	-	-
Long Term Debt	17	22	27	30	30	29	30	29	30	30	-	-
Other Liabilities Noncurrent	-	0	0	0	0	0	-	-	-	0	-	-
Liabilities	46	52	49	55	49	57	50	45	39	43	6	9
Stockholders Equity
Preferred Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	555	517	514	512	509	507	505	502	500	489	487	363
Retained Earnings Accumulated Deficit	-467	-446	-421	-395	-354	-325	-288	-258	-238	-223	-206	-193
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	0	-0	1	-0	-0	0	-1	-1
Stockholders Equity	87	70	93	117	156	182	217	244	262	267	280	169
Liabilities And Stockholders Equity	134	123	142	172	204	239	267	289	301	310	286	177
Preferred Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Authorized	10	10	10	10	10	10	10	10	10	10	10	10
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Par Or Stated Value Per Share	0	0	0	0	0	0	0	0	0	0	0	0
Common Stock Shares Authorized	300	300	300	300	300	300	300	300	300	300	300	300
Common Stock Shares Issued	72	61	61	61	61	60	60	60	60	58	58	41
Shares Outstanding	72	61	61	61	61	60	60	60	60	58	58	82

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	-13.31%	10.48%	-	-	-	-	-	-	-	-	-	-
2025	14.29%	10.48%	28.57%	14.29%	37.30%	75.40%	-4.62%	3.59%	33.33%	10.59%	-10.59%	-7.06%
2024	-29.00%	-37.40%	-18.97%	-19.86%	-14.44%	2.71%	-19.25%	-28.97%	-43.93%	-26.75%	-13.01%	-13.01%
2023	-	-	-	-12.71%	-40.71%	-65.43%	36.45%	98.03%	46.31%	-16.00%	-2.67%	-29.60%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	4.55	4.07	6.02	5.97	8.02	6.46	10.43	17.37	30.20	19.01	35.85	17.53
Quick Ratio	4.39	3.89	5.77	5.77	7.72	6.21	10.06	16.95	29.81	18.77	35.33	16.98
Working Capital	103.87M	92.25M	110.20M	123.54M	135.63M	150.70M	187.72M	251.55M	247.36M	233.64M	212.50M	141.01M
Leverage & Debt
Debt to Equity	0.53	0.74	0.53	0.47	0.31	0.31	0.23	0.18	0.15	0.16	0.02	0.05
Interest Coverage TTM	-26.84	-29.32	-33.12	-34.84	-30.95	-28.03	-25.72	-13.43	-9.98	-8.24	-6.91	-9.05
Debt Ratio	0.35	0.43	0.34	0.32	0.24	0.24	0.19	0.16	0.13	0.14	0.02	0.05
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.01	0.01	0.02	0.02	0.01	0.01	0.01
Per Share Metrics
Diluted EPS TTM	-1.79	-2.00	-2.20	-2.26	-1.92	-1.71	-1.36	-1.08	-0.94	-1.08	-0.90	-0.57
Free Cash Flow Per Share TTM	-1.67	-1.91	-2.04	-1.95	-1.69	-1.44	-1.12	-0.93	-0.85	-0.89	-0.85	-0.52
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Operating Profit Margin TTM	-	-	-	-	-	-2,846.87%	-2,319.75%	-1,914.61%	-1,642.37%	-3,337.23%	-3,105.95%	-2,851.15%
Net Profit Margin TTM	-	-	-	-	-	-2,555.03%	-2,039.25%	-1,619.58%	-1,396.68%	-2,858.68%	-2,660.48%	-2,537.83%
Growth Metrics
Net Revenue Growth (1Y)	-	-100.00%	-100.00%	-100.00%	-100.00%	118.61%	118.61%	118.61%	118.61%	-	-	-
Net Income Growth (1Y)	-2.56%	18.57%	63.28%	110.69%	107.83%	95.39%	67.57%	39.51%	24.21%	22.20%	-25.40%	-20.56%
EPS Growth (1Y)	-6.71%	17.50%	61.95%	108.98%	105.38%	58.26%	51.25%	90.53%	70.39%	104.14%	11.43%	-21.59%
Valuation Metrics
P/E TTM	-1.32	-1.05	-0.78	-0.51	-0.57	-1.01	-1.82	-2.24	-4.33	-3.56	-4.62	-8.49
P/B TTM	1.71	1.81	1.11	0.60	0.43	0.57	0.69	0.60	0.92	0.70	0.80	2.34
P/S TTM	-	-	-	-	-	25.77	37.20	36.30	60.48	101.89	122.85	215.43
Market Cap	149.20M	127.79M	103.58M	70.27M	66.58M	103.22M	149.00M	145.39M	242.24M	186.66M	225.05M	394.66M
Enterprise Value	128.22M	104.73M	87.17M	63.11M	65.72M	96.78M	145.25M	106.58M	225.28M	149.44M	129.95M	317.41M
Calculated Values
Free Cash Flow TTM	-105.55M	-115.63M	-123.75M	-117.85M	-102.56M	-86.23M	-67.34M	-55.66M	-50.78M	-43.09M	-46.00M	-42.35M
Net Debt	-20.98M	-23.06M	-16.41M	-7.16M	-863.00K	-6.44M	-3.75M	-38.81M	-16.96M	-37.22M	-95.11M	-77.25M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-06-17Sale

Owner: Porter, Derrell

Title: -

Shares: 13,040

Price/Share: $2.33

Value: $30,383.20

Shares Owned: 35,500

Relationship: Director

Ownership: Direct

2026-06-09Sale

Owner: Fountain, Nathan B

Title: -

Shares: 6,400

Price/Share: $2.23

Value: $14,272.00

Shares Owned: 48,150

Relationship: Director

Ownership: Direct

2026-03-06Sale

Owner: Meisner, Derek M

Title: Chief Legal Officer & Corp Sec

Shares: 2,090

Price/Share: $3.26

Value: $6,813.40

Shares Owned: 173,999

Relationship: Officer

Ownership: Direct

2026-02-27Sale

Owner: Meisner, Derek M

Title: Chief Legal Officer & Corp Sec

Shares: 9,406

Price/Share: $3.01

Value: $28,312.06

Shares Owned: 173,999

Relationship: Officer

Ownership: Direct

2026-01-28Sale

Owner: Meisner, Derek M

Title: Chief Legal Officer & Corp Sec

Shares: 2,671

Price/Share: $3.00

Value: $8,013.00

Shares Owned: 173,999

Relationship: Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-06-17	Porter, Derrell	Director	-	Direct	Sale	13,040	2.33	$30,383.20	35,500	4
2026-06-09	Fountain, Nathan B	Director	-	Direct	Sale	6,400	2.23	$14,272.00	48,150	4
2026-03-06	Meisner, Derek M	Officer	Chief Legal Officer & Corp Sec	Direct	Sale	2,090	3.26	$6,813.40	173,999	4
2026-02-27	Meisner, Derek M	Officer	Chief Legal Officer & Corp Sec	Direct	Sale	9,406	3.01	$28,312.06	173,999	4
2026-01-28	Meisner, Derek M	Officer	Chief Legal Officer & Corp Sec	Direct	Sale	2,671	3.00	$8,013.00	173,999	4
2026-01-23	Meisner, Derek M	Officer	Chief Legal Officer & Corp Sec	Direct	Sale	5,633	1.90	$10,702.70	173,999	4
2026-01-22	Oconnell, Daniel Joseph	Director,Officer	Chief Executive Officer	Direct	Sale	2,689	1.88	$5,055.32	881,275	4
2026-01-22	Barton, Russell	Officer	Chief Operating Officer	Direct	Sale	462	1.84	$850.08	205,092	4
2026-01-22	Zuga, Matt	Officer	CFO & Chief Business Officer	Direct	Sale	1,687	1.86	$3,137.82	304,924	4
2026-01-22	Siemers, Eric	Officer	Chief Medical Officer	Direct	Sale	895	1.82	$1,628.90	255,371	4
2026-01-12	Meisner, Derek M	Officer	Chief Legal Officer & Corp Sec	Direct	Sale	8,548	1.71	$14,617.08	83,800	4
2026-01-12	Oconnell, Daniel Joseph	Director,Officer	Chief Executive Officer	Direct	Sale	5,388	1.73	$9,321.24	593,510	4
2026-01-08	Doherty, James J.	Officer	President and CDO	Direct	Sale	6,467	1.82	$11,769.94	54,033	4
2026-01-08	Zuga, Matt	Officer	CFO & Chief Business Officer	Direct	Sale	6,888	1.82	$12,536.16	209,951	4
2026-01-08	Barton, Russell	Officer	Chief Operating Officer	Direct	Sale	3,530	1.86	$6,565.80	123,269	4
2026-01-07	Barton, Russell	Officer	Chief Operating Officer	Direct	Sale	1,700	1.99	$3,383.00	126,799	4
2026-01-07	Meisner, Derek M	Officer	Chief Legal Officer & Corp Sec	Direct	Sale	11,770	1.99	$23,422.30	134,459	4
2026-01-07	Zuga, Matt	Officer	CFO & Chief Business Officer	Direct	Sale	5,805	2.00	$11,610.00	216,839	4
2026-01-07	Schacterle, Amy	Officer	Chief Regulatory Officer	Direct	Sale	1,097	1.98	$2,172.06	7,703	4
2026-01-07	Oconnell, Daniel Joseph	Director,Officer	Chief Executive Officer	Direct	Sale	37,755	1.99	$75,132.45	619,982	4
2026-01-06	Siemers, Eric	Officer	Chief Medical Officer	Direct	Sale	6,834	1.97	$13,462.98	159,464	4
2025-01-23	Zuga, Matt	Officer	CFO & Chief Business Officer	Direct	Sale	28,902	1.72	$49,711.44	231,744	4
2025-01-21	Meisner, Derek M	Officer	Chief Legal Officer & Corp Sec	Direct	Sale	3,418	1.59	$5,434.62	161,127	4
2025-01-21	Oconnell, Daniel Joseph	Director,Officer	Chief Executive Officer	Direct	Sale	12,619	1.59	$20,064.21	667,488	4
2025-01-21	Siemers, Eric	Officer	Chief Medical Officer	Direct	Sale	3,219	1.59	$5,118.21	170,298	4
2025-01-21	Barton, Russell	Officer	Chief Operating Officer	Direct	Sale	2,914	1.61	$4,691.54	136,117	4
2025-01-03	Siemers, Eric	Officer	Chief Medical Officer	Direct	Sale	10,859	1.85	$20,089.15	106,717	4
2025-01-03	Barton, Russell	Officer	Chief Operating Officer	Direct	Sale	7,636	1.86	$14,202.96	89,231	4
2025-01-03	Oconnell, Daniel Joseph	Director,Officer	Chief Executive Officer	Direct	Sale	47,778	1.84	$87,911.52	454,707	4
2025-01-03	Meisner, Derek M	Officer	Chief Legal Officer & Corp Sec	Direct	Sale	11,122	1.84	$20,464.48	97,745	4
2025-01-03	Zuga, Matt	Officer	CFO & Chief Business Officer	Direct	Sale	13,235	1.84	$24,352.40	198,210	4
2024-01-19	Meisner, Derek M	Officer	Chief Legal Officer & Corp Sec	Direct	Sale	8,933	3.48	$31,086.84	108,867	4
2024-01-19	Oconnell, Daniel Joseph	Director,Officer	President and CEO	Direct	Sale	15,200	3.47	$52,744.00	502,485	4
2024-01-18	Barton, Russell	Officer	Chief Operating Officer	Direct	Sale	2,833	3.73	$10,567.09	96,867	4
2024-01-18	Zuga, Matt	Officer	CFO & Chief Business Officer	Direct	Sale	4,242	3.71	$15,737.82	211,445	4
2024-01-18	Siemers, Eric	Officer	Chief Medical Officer	Direct	Sale	3,124	3.71	$11,590.04	117,576	4
2023-08-17	Ives, Jeffrey L.	Director	-	Direct	Sale	41,949	6.57	$275,604.93	0	4
2023-07-21	Ra, Capital Management, L…	Director,TenPercentOwner	-	Indirect	Purchase	5,161,290	7.75	$39,999,997.50	13,043,179	4
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

71.31%

Inst. Shares: 45,081,869

Shares Outstanding: 63,219,289

2025-12-31

57.95%

Inst. Shares: 35,095,537

Shares Outstanding: 60,561,836

2025-09-30

58.12%

Inst. Shares: 35,204,581

Shares Outstanding: 60,573,425

2025-06-30

61.93%

Inst. Shares: 37,511,595

Shares Outstanding: 60,573,425

2025-03-31

66.25%

Inst. Shares: 40,098,871

Shares Outstanding: 60,525,628

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	45,081,869	63,219,289	71.31%
2025-12-31	35,095,537	60,561,836	57.95%
2025-09-30	35,204,581	60,573,425	58.12%
2025-06-30	37,511,595	60,573,425	61.93%
2025-03-31	40,098,871	60,525,628	66.25%
2024-12-31	42,349,776	60,013,277	70.57%
2024-09-30	42,624,712	60,079,778	70.95%
2024-06-30	42,445,471	60,079,778	70.65%
2024-03-31	42,038,254	59,812,000	70.28%
2023-12-31	38,222,773	48,609,383	78.63%
2023-09-30	43,018,236	54,229,630	79.33%
2023-06-30	24,575,880	82,050,124	29.95%
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial

Acumen Pharmaceuticals, Inc. (ABOS) — SEC Financial Statements & Analysis

Acumen Pharmaceuticals, Inc. (ABOS) is a biological products, (no diagnostic substances) company, incorporated in DE. Acumen Pharmaceuticals, Inc. trades on Nasdaq as: ABOS. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Acumen Pharmaceuticals, Inc. reported a -100.00% year-over-year revenue growth, a Debt-to-Equity ratio of 0.53x, a Price-to-Sales (P/S) ratio of 25.77x (TTM), a Price-to-Book (P/B) ratio of 1.71 (TTM), at a market cap of $149.20M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: -100.00%
Debt To Equity: 0.53x
P/S TTM: 25.77x
P/B TTM: 1.71
Market Cap: $149.20M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Acumen Pharmaceuticals, Inc. in?

Acumen Pharmaceuticals, Inc. (ABOS) operates in the Biological Products, (No Diagnostic Substances) industry.

What is ABOS's market cap?

Acumen Pharmaceuticals, Inc. (ABOS) has a market capitalization of $149.20M as of 2026-03-31.

What exchange does ABOS trade on?

Acumen Pharmaceuticals, Inc. (ABOS) trades on the Nasdaq.

Where is Acumen Pharmaceuticals, Inc. incorporated?

Acumen Pharmaceuticals, Inc. is incorporated in DE.

Acumen Pharmaceuticals, Inc. (ABOS) — SEC Financial Statements & Analysis

Frequently Asked Questions

Research Faster.Invest Smarter.

Research Faster.
Invest Smarter.